Aims: To investigate the effect of miR-195 overexpression on radiosensitivity and the relevant molecular mechanisms in breast cancer.
Methods: miR-195 mimics were transfected to breast cancer cell line MCF-7 by gene transfection; miR-195 expression level in cells was determined by real-time quantitative PCR. Cellular viability was observed by colony formation assay after the cells were irradiated with X-ray. Apoptosis was detected by annexin V/propidium iodide (PI) staining. Protein expression was evaluated by Western blot assay.
Results: After miR-195 mimics were transfected, miR-195 expression in breast cancer cells was significantly upregulated (P < 0.05). miR-195 overexpression significantly enhanced the response to radiation of MCF-7 cells with a decrease in colony survival at individual doses of X-ray (P < 0.05). After the cells were irradiated with 5 Gy, apoptotic rate was significantly increased in miR-195-overexpressed group with a rate of 18.13% ± 1.57%; moreover, BCL-2 protein expression was significantly downregulated (P < 0.05).
Conclusion: Exogenetic miR-195 expression could significantly enhance the radiosensitivity of human breast cancer cells; this finding may be attributed to BCL-2 downregulation to promote radiation-induced apoptosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538095 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Data pharmacovigilance analysis of medroxyprogesterone-related adverse events in the FDA adverse event reporting system.
Expert Opin Drug Saf
January 2025
Department of Obstetrics, The Affiliated Hospital of Qingdao University, Qingdao, China.
Objectives: Medroxyprogesterone acetate (MPA), a steroid progesterone, is widely used to treat endometriosis, menstrual disorders, and uterine bleeding in clinical practice. However, the safety profile of MPA requires comprehensive evaluation.
Methods: This study performed a retrospective analysis using real-world data extracted from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Beyond Boundaries in ERBB2-Positive Brain Metastatic Breast Cancer.
JAMA Netw Open
January 2025
Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Survival Among Patients With ERBB2-Positive Metastatic Breast Cancer and Central Nervous System Disease.
JAMA Netw Open
January 2025
Department of Neurosurgery and Brain Metastasis Center, Memorial Sloan Kettering Cancer Center, New York, New York.
Importance: Approximately one-third of patients with ERBB2 (formerly HER2 or HER2/neu)-positive (ERBB2+) metastatic breast cancer (MBC) develop brain metastasis. It is unclear whether patients with disease limited to the central nervous system (CNS) have different outcomes and causes of death compared with those with concomitant extracranial metastasis.
Objective: To assess overall survival (OS) and CNS-related mortality among patients with ERBB2+ breast cancer and a diagnosis of CNS disease by disease distribution (CNS only vs CNS plus extracranial metastasis).
Formation and evaluation of doxorubicin and cromoglycate metal-organic framework for anti-cancer activity.
Nanomedicine (Lond)
January 2025
Department of Chemistry, The University of Jordan, Amman, Jordan.
Aims: We develop and evaluate copper-based metal-organic frameworks (Cu-MOFs) incorporating cromolyn as a linker to enhance structural stability, drug delivery efficiency, and therapeutic potential, particularly for breast cancer treatment.
Materials & Methods: Two Cu-MOF formulations were synthesized: Cu-MOFs-BDC-DOX (using terephthalic acid) and Cu-MOFs-CROMO-DOX (using cromolyn as a linker). Characterization was performed using SEM/TEM for morphology, and FTIR, XRD, and TGA to confirm structural integrity.
NELBI score: a new clinical calculator of thirty-day mortality following systemic anticancer therapy in breast cancer patients near the end of life.
Breast Cancer
January 2025
Health Sciences University, Dr Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, Turkey.
Aims And Objectives: Appropriately timed cessation of systemic anticancer treatments is an important part of a patient's quality of life (QoL). We aimed to determine the right time to discontinue systemic anticancer therapy (SACT) and switch to the best supportive care for patients with advanced breast cancer (BC) who are nearing the end of life.
Methods: We identified 200 BC patients who died within 30 days after palliative SACT.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!